- IMS Health and Reltio Form Alliance to Deploy Advanced Information Management Solutions for Life Sciences
- IMS Health Study: Global Market for Cancer Treatments Grows to $107 Billion in 2015, Fueled by Record Level of Innovation
- IMS Health Acquires Privacy Analytics, Advancing Real-World Evidence Technology to Drive R&D and Commercial Performance
- IMS Health Reports First-Quarter 2016 Results
- IMS Health and Quintiles to Merge; Quintiles IMS to Become Industry-Leading Information and Technology-Enabled Healthcare Service Provider
- IMS Health to Announce First-Quarter 2016 Results On May 4, 2016
- IMS Health Named a Leading Outsourcing Provider by International Association of Outsourcing Professionals
- IMS Health Study: U.S. Drug Spending Growth Reaches 8.5 Percent in 2015
- IMS Health: Surge in Biosimilars to Drive Significant Change in Health System Costs, Patient Access and Competition by 2020
- IMS Health and Hootsuite Form Alliance to Help Life Sciences Companies Increase Engagement on Social Media Channels and Support Compliance
- Servier Russia Deploys IMS Health’s Nexxus Mobile Intelligence CRM Solution to Drive Commercial Effectiveness
- IMS Health to Deliver Keynote Address on Orchestrated Customer Engagement at eyeforpharma Barcelona 2016
Pharmaceutical Market Europe: Transformational Technology: Big data, the cloud and the value of insights
The advent of the big data era has produced a big challenge for pharma and, with the continued growth and influence of mobile, wearable devices, machine learning and the internet-of-things, the size of the challenge won’t be shrinking any time soon.
Reuters: U.S. prescription drug spending to hit $400 billion a year by 2020: IMS
U.S. annual spending on prescription medicines will increase 22 percent over the next five years, climbing as high as $400 billion in 2020, according to a report released by health care information company IMS Health Holdings Inc on Thursday.
Bloomberg: Prescription Drug Spending Hits Record $425 Billion in U.S.
Spending on prescription drugs in the U.S. rose 12 percent to a record $425 billion before discounts last year, boosted in part by the introduction of breakthrough medicines for cancer and the growing number of patients seeking treatment for hepatitis C.
Wall Street Journal: U.S. Drug Spending Climbs
Total spending on prescription drugs in the U.S. rose 12.2% to nearly $425 billion in 2015, continuing a steep climb fueled by the introduction in recent years of expensive new drugs for cancer and infections, as well as price hikes for older drugs, according to a new report.
Associated Press: Report: US medicine spending up 8.5 percent 2015
A report from data firm IMS Health estimates patients, insurers, government programs and other payers spent a combined $309.5 billion last year on prescription medicines.
Forbes: Double-Digit Growth In Drug Spending Slows As Insurers Fight Back
Thanks to rebates and other concessions awarded by pharma companies angling to get their new products onto insurance formularies, the net spending on drugs was $310 billion in 2015, growing only 8.5% from the previous year. And the average net price for existing brands rose just 2.8%—a significantly lower rate of growth than what was seen in previous years.
Healthcare BPO: IMS Health Shares Benefits and Trends of Outsourcing within the Healthcare Industry
A recent study of the Global Healthcare Business Process Outsourcing (BPO) by Research and Markets, Global Healthcare BPO Market 2015 – 2019, indicates growth at a compound annual growth rate of 5.32 percent over the period of 2014 to 2019.
Which Way Now For Mid-Sized European Pharmas?
Compared with their top 20 European peers and with similarly sized companies in the US, many mid-sized European pharmas are struggling. IMS Health analyzes the predicament these companies find themselves in and outlines what they need to do to avoid being caught in an evolutionary backwater.
7 Stunning Findings Regarding Global Medicine Use by 2020
The Motley Fool
What does the future hold for global drug spending? According to the latest report from the IMS Institute for Healthcare Informatics, there are a number of surprising findings.
Identifying Switch Opportunities Worldwide
IMS Health's Andy Tisman is featured in this OTCToolBox Innovations article sharing key consumer health insights regarding the global trend of switching medicines from prescription to non-prescription status.
Cloud Marketing: Cloud Control
To unlock the vast business potential of the cloud, pharma must first overcome its inherent resistance to change and then commit to tearing down those silo walls.
- Pharmaceutical Market Europe: Transformational Technology: Big data, the cloud and the value of insights